Journal: Cell reports

Article Title: Distinct features of a peripheral T helper subset that drives the B cell response in dengue virus infection

doi: 10.1016/j.celrep.2025.115366

Figure Lengend Snippet:

Article Snippet: A human CXCL13/BLC/BCA-1 Quantikine ELISA Kit (R&D Systems) was used to measure the CXCL13 cytokine concentration in plasma samples as a circulating GC marker.

Techniques: Purification, Virus, Recombinant, Lysis, Staining, Electron Microscopy, Enzyme-linked Immunospot, Enzyme-linked Immunosorbent Assay, Amplification, Gene Expression, Software

Journal:

Article Title: BCA-1 is highly expressed in Helicobacter pylori -induced mucosa-associated lymphoid tissue and gastric lymphoma

doi:

Figure Lengend Snippet: In situ expression of BCA-1 in chronic Hp gastritis. Expression is observed in the whole area of lymphoid aggregates (a) and is restricted to the mantle zone in secondary lymphoid follicles (c). Intermediate distribution (b) is found occasionally. (d–f) Localization of follicular dendritic cells as detected in serial sections by immunohistochemical staining for CD21. Bottom: In situ expression of BCA-1 in a secondary follicle of a normal lymph node. Antisense and sense hybridization is shown. ×100 (original magnification).

Article Snippet: Goat anti-human BCA-1 (1:100; R&D Systems Inc., Minneapolis, Minnesota, USA) and rabbit anti-human CXCR5 (IgG purified, 1:100) were used to detect BCA-1 and its receptor.

Techniques: In Situ, Expressing, Immunohistochemical staining, Staining, Hybridization

Journal:

Article Title: BCA-1 is highly expressed in Helicobacter pylori -induced mucosa-associated lymphoid tissue and gastric lymphoma

doi:

Figure Lengend Snippet: BCA-1 and CXCR5 expression in chronic Hp gastritis. (a) In situ expression of BCA-1 is shown in the mantle zone of a secondary lymphoid follicle. The sense probe control (b) and staining for B lymphocytes (CD20+) (c) are shown in serial sections of the same follicle. ×100 (original magnification). BCA-1 (d) and CXCR5 (f) immunostaining is shown with the corresponding isotype-matched controls (e and g). Staining of a frozen section of a tonsil (h) and control (i) shows BCA-1 in association with small round and stellate cells, suggesting expression by lymphocytes and dendritic cells. ×200 (original magnification).

Article Snippet: Goat anti-human BCA-1 (1:100; R&D Systems Inc., Minneapolis, Minnesota, USA) and rabbit anti-human CXCR5 (IgG purified, 1:100) were used to detect BCA-1 and its receptor.

Techniques: Expressing, In Situ, Staining, Immunostaining

Journal:

Article Title: BCA-1 is highly expressed in Helicobacter pylori -induced mucosa-associated lymphoid tissue and gastric lymphoma

doi:

Figure Lengend Snippet: Expression of BCA-1 and CXCR5 in gastric MALT lymphomas. In situ expression of BCA-1 in (a) low-grade lymphoma with surrounding normal gastric mucosa, ×40 (original magnification); and in high-grade lymphoma (b and c), ×200 and ×400, respectively (original magnification). Immunostaining of BCA-1 and CXCR5 in high-grade lymphoma (d and e), ×400 and ×200, respectively (original magnification).

Article Snippet: Goat anti-human BCA-1 (1:100; R&D Systems Inc., Minneapolis, Minnesota, USA) and rabbit anti-human CXCR5 (IgG purified, 1:100) were used to detect BCA-1 and its receptor.

Techniques: Expressing, In Situ, Immunostaining

Journal: Cancer immunology research

Article Title: Radiofrequency ablation remodels the tumor microenvironment and promotes neutrophil-mediated abscopal immunomodulation in pancreatic cancer

doi: 10.1158/2326-6066.CIR-22-0379

Figure Lengend Snippet: Tumor size was recorded 4 days before (Initial), right before (Pre) and 4 days after (Post) Sham or RFA treatment. Proteome arrays were performed in locally ablated tumors and serum of ablated mice and compared to Sham-treated mice (Control). A, Experimental design of RFA-treated mice. B, Growth curves show Control tumors (n = 8) significantly increased in size 4 days after treatment when compared to RFA-treated (n = 8) and non-RFA treated (n = 7) tumors. C, At the time of euthanization only Sham-treated tumors (n = 8) had significantly increased in size compared with pretreatment size; no difference in size was observed in RFA-treated (n = 8) and non-RFA treated (n = 7) tumors Pre and Post RFA. D, ImageJ quantification of necrosis, which was detected by H&E staining. RFA significantly increased necrosis on the RFA- and non-RFA-treated tumors compared to control Sham-treated tumors. E, Representative composite H&E staining of control, RFA, and non-RFA treated tumors showing necrotic areas inside dashed lines. F, ImageJ quantification showing RFA increased cleaved caspase 3+ cells in the RFA-treated and non-RFA treated tumors compared to control Sham-treated control tumors, as assessed by IHC. G, Representative IHC staining for cleaved caspase 3 in control, RFA, and non-RFA treated tumors. H, ImageJ quantification revealed RFA significantly increased the number of granzyme B+ cells in the RFA-treated tumors compared to controls and non-RFA treated tumors, as assessed by IHC. I, IHC staining for granzyme B in control, RFA, and non-RFA treated tumors. J, RFA-treated tumors (n = 3) presented increased expression of C5/C5a, IL-23 and CXCL12 compared to control (n = 2) tumor content. K, CXCL10, CXCL12, CXCL13 and TIMP-1 were significantly elevated in serum from RFA-treated (n = 4) mice compared to Sham-treated (n = 3) control serum. Time x Treatment comparisons were performed using Two-way ANOVA, treatment only comparisons by One-way ANOVA and proteome arrays were analyzed by multiple t test. Bar plots showing mean with SEM were used to represent data. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; n.s., not significant. Scale bars are 50μM.

Article Snippet: CXCL13 ELISA Mouse CXCL13/BLC/BCA-1 Quantikine ELISA Kit assay was used to determine CXCL13 levels in mouse serum, splenocytes and tumors homogenates, following the manufacturer instructions (R&D Systems, cat #MCX130).

Techniques: Control, Staining, Immunohistochemistry, Expressing

Journal: Cancer immunology research

Article Title: Radiofrequency ablation remodels the tumor microenvironment and promotes neutrophil-mediated abscopal immunomodulation in pancreatic cancer

doi: 10.1158/2326-6066.CIR-22-0379

Figure Lengend Snippet: A-B, IMC analysis of tumors 4 days after Sham or RFA treatment revealed Ly6G+CD11b+CD44+ neutrophils are enriched in non-RFA treated tumors. C, Neighborhood analysis identified immune cells and markers with strong neutrophil co-localization. D, Cluster and Cell Phenotype information of Neighborhood analysis of IMC data. E, Experimental design for neutrophil depletion in vivo followed by RFA. F, RFA locally ablated tumors treated with IgG2a isotype control (VEH, n = 6) or anti-Ly6G (ND, n = 8) did not show differences in tumor size right before (Pre) and 4 days after (Post) RFA ablation. In non-RFA treated tumors, anti-Ly6G (ND, n = 8) treatment revealed an increase in tumor size Post RFA treatment when compared to IgG2a isotype control (VEH, n = 6) treated tumors. G, Neutrophil depletion (ND; anti-Ly6G treated group) did not alter αSMA staining, detected by IHC, in RFA-treated tumors when compared to RFA-treated tumors with IgG2a (VEH); on the contrary, neutrophil depletion (ND) revealed non-RFA treated tumors presented a significant increase in αSMA compared to control non-neutrophil depleted (VEH) group. H, Neutrophil depletion did not alter CD31 staining, detected by IHC, in any of the groups. I, Neutrophil-depleted RFA treated tumors presented a significant reduction in CXCL13 content compared to both VEH + RFA and non-RFA treated tumors when assayed using a cytokine array. No differences were found in non-RFA treated tumors between treatments. J, Neutrophil depletion presented a trend in reducing systemic CXCL13 levels in RFA treated mice. Tumor volume was analyzed by paired Student’s t test. Tumor chemokine levels were studied by Two-way ANOVA. IHC and serum protein expression levels were analyzed by unpaired Student’s t test. Bar plots indicate mean with SEM. *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001; n.s., not significant.

Article Snippet: CXCL13 ELISA Mouse CXCL13/BLC/BCA-1 Quantikine ELISA Kit assay was used to determine CXCL13 levels in mouse serum, splenocytes and tumors homogenates, following the manufacturer instructions (R&D Systems, cat #MCX130).

Techniques: In Vivo, Control, Staining, Expressing